No Data
No Data
Lifevantage Shares Are Trading Higher After the Company Announced the Completion of a Successful 12-week Clinical Trial on Its New GLP-1 System for Weight Loss.
LifeVantage Completes Successful Human Clinical Trial With New GLP-1 System for Activated Weight Loss* †
Investors in LifeVantage (NASDAQ:LFVN) Have Seen Notable Returns of 69% Over the Past Year
LifeVantage Corporation's (NASDAQ:LFVN) 25% Share Price Surge Not Quite Adding Up
LifeVantage's In Vitro Study Shows Increase In GLP-1 Production, Stock Up
Express News | LifeVantage Corp - New GLP-1 System to Be Introduced in October
No Data
No Data